搜索结果
靶点ID:TCMBANKGE000334
靶点别名:ERYF1; GATA-1; GF-1; GF1; NF-E1; NFE1; XLANP; XLTDA; XLTT
靶点描述:GATA binding protein 1
染色体:X
染色体位置:Xp11.23
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:4170
OMIM_Link:305371
Ensembl_Link:ENSG00000102145
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN036834 | wogonoside | wogoninoglucuronide; N2501; wogonoside ; (2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-5-(5-hydroxy-8-methoxy-4-oxo-2-phenylchromen-7-yl)-6-oxohexanoic acid; AC-20339; ZINC21992923; Y0212; BG01748878; AKOS015965557 | C22H20O12 | 476.387 | [C@]1([H])(O[H])[C@@]([H])(C(=O)O[H])O[C@@]([H])(Oc2c(OC([H])([H])[H])c(OC(c3c([H])c([H])c([H])c([H])c3[H])=C([H])C4=O)c4c(O[H])c2O[H])[C@]([H])(O[H])[C@@]1([H])O[H] |
| TCMBANKIN058074 | chebulin | C18H32O2 | 280.45 | C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C3C(C(C(O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5C(C(C(=O)O3)CC(=O)O)C(C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O | |
| TCMBANKIN058288 | catechol | 430749_ALDRICH; Catechin (phenol); Pyrokatechin [Czech]; NCGC00015283-01; Catechol-UL-14C; NCI-C55856; CI Oxidation Base 26; CHEBI:18135; benzene-1,2-diol; C15571; 120-80-9; InChI=1/C6H6O2/c7-5-3-1-2-4-6(5)8/h1-4,7-8; C9510_SIAL; Fouramine PCH; 135011_SIAL; Lopac-C-9510; 2-hydroxyphenol; NSC 1573; NCGC00091262-01; Fourrine 68; o-Diphenol; C.I. Oxidation Base 26; o-Dioxybenzene; C00090; ST5214346; (1,2,3,4,5,6-(1)?C?)BENZENE-1,2-DIOL; AB-131/40235236; Lopac0_000280; ortho-Benzenediol; Catechol (phenol); ortho-Hydroquinone; ZINC00330145; 16474-90-1; pyrocatechol; benzenediol; Brenzcatechin; 12385-08-9; C01785; EINECS 204-427-5; EU-0100280; nchembio801-comp10; o-Dihydroxybenzene; Durafur Developer CFouramine PCH; o-Hydroxyphenol; Phthalhydroquinone; 16474-89-8; Catechol-pyrocatechol; CCRIS 741; ACM19481108; AI3-03995; Pyrocatechinic acid; CI 76500; Durafur developer C; o-Phenylenediol; 1,2-dihydroxybenzene; ortho-Hydroxyphenol; Oxyphenic acid; BRN 0471401; c0097; pyrocatechol-ul-14C; CAQ; 37349-32-9; ortho-Dihydroxybenzene; AIDS-108194; C3561_SIAL; o-Benzenediol; ortho-Dioxybenzene; Katechol [Czech]; Pelagol Grey C; Pyrokatechol [Czech]; AIDS108194; Pyrocatechinic acidPyrocatechol; WLN: QR BQ; Pyrocatechine; 1,2-benzenediol; o-Hydroquinone; CATECHOL; Benzene, o-dihydroxy-; pyrocatechin; ortho-Phenylenediol; HSDB 1436; C9593_SIGMA; NSC1573; C.I. 76500;pyrocatechol;o-hydroquinone;o-phenylenediol;1,2-benzenediol | C6H6O2 | 110.11 g/mol | C1=CC=C(C(=C1)O)O |
| TCMBANKIN059159 | capsaicin | 8-Methyl-N-vanillyl-6-nonenamide, (E)-; AKOS007930159; Bio-0615; GTPL2486; Bio2_000748; EPA Pesticide Chemical Code 070701; Zostrix HP; S07O44R1ZM; TC-030399; 360376_ALDRICH; NCGC00017337-07; Citrus Aurantium 30%; AK589917; ZOSTRIX (TN); HMS2230O23; D0U5CE; HMS1989N10; IDI1_034018; DSSTox_GSID_20241; Isodecenoic acid vanillylamide; NGX-7325; NCGC00017337-04; HMS1791N10; NCGC00090853-08; NCGC00090853-11; KBio3_000536; (E)-8-Methyl-N-vanillyl-6-nonenamide(8cl); NSC-757844; M2028_SIGMA; E-CAPSAICIN; Capsaicin, from Capsicum sp., >=50% (HPLC); (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; MCULE-8056866140; Capsaicin [USP:INN]; NCGC00257869-01; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; DB06774; trans-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; SMR000718774; KBioGR_000268; MEGxp0_001448; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; Caswell No. 158; Prestwick2_000879; KBio1_000354; FEMA No. 3404; Capsaicin, analytical standard; N735; HMS3649N15; SBI-0052593.P002; AJ-26667; BRD-K50590187-001-06-6; CAS_404-86-4; NCGC00017337-02; HMS1921H11; 8-Methyl-N-vanillyl-trans-6-nonenamide; 21750_FLUKA; ZINC01530575; Vanilloid; YKPUWZUDDOIDPM-SOFGYWHQSA-N; MR3H3; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; HMS1570P19; capsaicin ; Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8 -methyl-, (E)-; KBio3_000535; Zostrix (TN); KBio2_000783; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)-; NCGC00017337-06; Capsaicin, European Pharmacopoeia (EP) Reference Standard; Capsicin; N-(3-Methoxy-4-hydroxybenzyl)-8-methyl-6-nonenamide; KBioSS_000783; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; Bitter orange extract 30%; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; SR-05000001861-5; Capsaicin, certified reference material, TraceCERT(R); CAPSAICIN, NATURAL; DSSTox_RID_75455; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; Capsaicin, Pharmaceutical Secondary Standard; Certified Reference Material; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; depletes Substance P; trans-8-Methyl-N-vanillyl-6-nonenamide; BDBM20461; MolPort-001-742-263; 1217899-52-9; NCGC00090853-03; SR-05000001861; Spectrum_000303; UPCMLD-DP092:001; Capsaicin, >=95%, from Capsicum sp.; Capsaicin (transdermal patch formulation, neuropathic pain); I01-2469; Nonenamide, 8-methyl-N-vanillyl-, (E)-; SR-05000001861-9; CC0144; Transacin; AC1Q46B3; SDCCGMLS-0066678.P001; SR-05000001861-6; Axsain; AN-23437; (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; (E)-N-(4-Hydroxy-3-methoxybenzyl); (E)8-methyl-N-vanillyl-6-Nonenamide; CCRIS 1588; Capsaicin (JAN/USP); Capsaicin (Natural); trans-Capsaicin-d3; N0C781; trans-8-Methyl-N-vanillylnon; M1149; SC-19636; (E)-N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-non-6-enamide; Styptysat; HMS2097P19; NCGC00017337-11; KBio3_002417; neurotoxic; CHEMBL294199; Capsaicin (in oleoresin of capsicum); NCGC00090853-01; N-(4-hydroxy-3-methoxy-benzyl)-8-methyl-non-6-enamide; Capsaicin [USAN]; Capsicine; NCGC00017337-08; NCGC00017337-09; C06866; N-[(4-hydroxy-3-methoxy-phenyl)methyl]nonanamide; NGX-1998; Tox21_110817; SCHEMBL8086; UNII-S07O44R1ZM; NSC 56353; (E)-N-[(4-HYDROXY-3-METHOXYPHENYL)METHYL]-8-METHYL-6-NONENAMIDE; BDBM86537; LMFA08020085; N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; KBio2_002836; trans-8-methyl-N-vanillyl-6-nonenamide; NCGC00090853-06; CHEBI:94524; NCGC00090853-09; NCGC00090853-02; Bio2_000268; HMS3402N10; Prestwick_204; Prestwick3_000879; 8-Methyl-N-vanillyl-6E-nonenamide; Spectrum4_001739; 8-Methyl-N-Vanillyl-6-Nonenamide; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; BSPBio_001548; LS-2138; Capsaicin, United States Pharmacopeia (USP) Reference Standard; KBioGR_002158; EINECS 206-969-8; Bio1_000468; SPBio_002878; KBio2_000268; MFCD00017259; Bio1_001446; nchembio862-comp2; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; NSC-56353; NSC757844; DTXSID9020241; Ausanil; HMS501B16; HMS2092D21; EI-125; NCGC00090853-04; AK113598; NCI-C56564; Qutenza; SR-05000001861-4; [(E)-N-(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; Adlea; MLS002154049; (E)-8-Methyl-N-vanillyl-6-nonenamide; Pharmakon1600-01501128; Spectrum5_000538; (e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; 6-Nonenamide, (E)-; SCHEMBL8085; AB00053098-11; Capsaicin [in oleoresin of capsicum]; CJ-23980; NCGC00017337-12; HSDB 954; NGX 4010; CAS-404-86-4; BRN 2816484; 4CH-016296; NSC56353; IDI1_000354; RTC-030399; (E)-Capsaicin; TL8002946; NCGC00017337-05; CS-1518; Mioton; BG01597556; DivK1c_000354; 12084_FLUKA; Bio1_000957; AC-10114; AC1LU7K3; UPCMLD-DP092; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; TQ-1018; FT-0082538; Zostrix; NCGC00017337-03; AB00053098_12; SPECTRUM1501128; KS-5181; Prestwick1_000879; Capsaicin, from natural source; NCGC00017337-13; n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide; Spectrum2_000770; NSC_2548; Prestwick0_000879; BPBio1_001053; NCGC00090853-10; C18H27NO3; NCGC00090853-12; W-5044; CAPSAICINE; SR-05000001861-1; Tox21_200315; HMS1361N10; D00250; (6E)-N-(4-Hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #; Spectrum3_001449; HY-10448; (E)-N-[(4-Hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide; BSPBio_002917; ST057183; KBio2_005919; ZINC1530575; SPBio_000820; N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; NCGC00017337-10; CCG-39908; STL372889; N-[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide; Capsaicin Patch; UPCMLD-DP092:002; NGX-3781; BBL027836; (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; Capsaicin (8-Methyl-N-vanillyl-6-nonenamide); 912457-62-6; HMS2089N11; Capsaicin; epsilon-capsaicin; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; NGX-4010; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)- (8CI); KBioSS_000268; 21748_FLUKA; Citrus Aurantium Extract; KBio2_005404; TNP00277; trans-Capsaicin; CHEBI:3374; Capsaicin(Qutenza); CITRUS AURANTIUM PE; CAPSAICIN (2444-46-4 NONIVAMIDE (SYNTHETIC CAPSAICIN)); N1667; BSPBio_000957; 4-13-00-02588 (Beilstein Handbook Reference); BRD-K37056290-001-01-1; KBio2_003351; NCGC00090853-07; SMP2_000337; NINDS_000354; Isodecenoate; DSSTox_CID_241; ALGRX 4975; 404-86-4; CAPSAICINOIDS;Vanilloid;campsiol;capsaicin | C18H27NO3 | 305.41 | CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000294 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI000771 | Skin and Connective Tissue Diseases | Abnormality of the integument; Abnormality of the immune system | Sign or Symptom | phenotype | |
| TCMBANKDI002490 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI002735 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases; Hemic and Lymphatic Diseases | Abnormality of the immune system; Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003411 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI003879 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Male Urogenital Diseases; Endocrine System Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
| TCMBANKDI004030 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI004407 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI005151 | - | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI006787 | Infections; Respiratory Tract Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007091 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI007163 | Musculoskeletal Diseases; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI007618 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | phenotype | |
| TCMBANKDI007737 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI008217 | - | Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI008567 | - | Abnormality of blood and blood-forming tissues | Finding | phenotype | |
| TCMBANKDI008736 | - | - | Finding | disease | |
| TCMBANKDI009299 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI009697 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI009702 | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | Abnormality of the cardiovascular system | Disease or Syndrome | phenotype | |
| TCMBANKDI009951 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI010276 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases | Abnormality of the cardiovascular system | Congenital Abnormality | disease | |
| TCMBANKDI010366 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | group | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI012238 | - | Abnormality of the integument | Finding | phenotype | |
| TCMBANKDI013495 | Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI014193 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI014430 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI016026 | Neoplasms; Eye Diseases | Neoplasm; Abnormality of the eye | Neoplastic Process | disease | |
| TCMBANKDI016778 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017308 | Endocrine System Diseases | Abnormality of the endocrine system; Growth abnormality | Pathologic Function | phenotype | |
| TCMBANKDI018275 | - | - | Finding | disease | |
| TCMBANKDI019522 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI019879 | Digestive System Diseases; Neoplasms; Endocrine System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI020449 | Skin and Connective Tissue Diseases | Abnormality of the integument | Pathologic Function | phenotype | |
| TCMBANKDI021339 | Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | group | |
| TCMBANKDI021382 | Pathological Conditions, Signs and Symptoms | Abnormality of the integument | Finding | phenotype | |
| TCMBANKDI021460 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI022757 | Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI023060 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Immune System Diseases; Hemic and Lymphatic Diseases | Abnormality of metabolism/homeostasis; Abnormality of prenatal development or birth | Disease or Syndrome | disease | |
| TCMBANKDI023751 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024559 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI024561 | - | - | Neoplastic Process | disease | |
| TCMBANKDI026556 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI027669 | - | - | Finding | phenotype | |
| TCMBANKDI028664 | - | - | Finding | phenotype | |
| TCMBANKDI028918 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Finding | phenotype | |
| TCMBANKDI028920 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI028963 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases; Hemic and Lymphatic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI029861 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI030041 | Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI030233 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Immune System Diseases; Hemic and Lymphatic Diseases | Abnormality of blood and blood-forming tissues | Disease or Syndrome | disease | |
| TCMBANKDI030940 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI031381 | Neoplasms; Hemic and Lymphatic Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI031879 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab